Sign In
Get Clay Free →

Suggestions

    Daniel Blumrich

    Senior Director - US Marketing Lead Neuroendocrine Tumors (NET) at Advanced Accelerator Applications

    Daniel Blumrich, PhD, is a senior pharmaceutical executive with expertise in oncology and neuroendocrine tumors (NET). He currently serves as the Senior Director and US Marketing Lead for Neuroendocrine Tumors at Advanced Accelerator Applications, a subsidiary of Novartis.

    Blumrich has a strong background in the pharmaceutical industry, particularly in oncology. Prior to his current role, he held positions at Bayer, where he worked as a Senior Area General Manager in US Oncology.2 His experience also includes involvement with pivotal studies in neuroendocrine tumors, such as the NETTER-1 study.1

    With a PhD from the DKFZ German Cancer Research Center, Blumrich has a solid foundation in cancer research.3 His career demonstrates a focus on advancing treatments and marketing strategies for oncology and neuroendocrine tumors, positioning him as a key figure in this specialized field of pharmaceutical development and marketing.

    Related Questions

    What are Daniel Blumrich's key achievements in the pharmaceutical industry?
    How has Daniel Blumrich contributed to the field of neuroendocrine tumors (NET)?
    What is the significance of the NETTER-1 study in the context of neuroendocrine tumors?
    What are Daniel Blumrich's educational background and professional experience?
    How does Daniel Blumrich's role at Advanced Accelerator Applications impact the company's mission?
    Daniel Blumrich
    Add to my network

    Location

    East Hanover, New Jersey, United States